Medtronic saw $8.4 billion in revenue with gains in its neuroscience portfolio during the second quarter of fiscal year 2025, according to financial results posted Nov. 19.
Five notes:
1. Quarterly revenue increased 5.3% year over year. The company's cardiovascular portfolio saw 6.1% growth year over year with $3.1 billion, and its medical surgical portfolio grew 1.2% year over year with $2.1 billion.
2. Medtronic's neuroscience portfolio saw a 7.1% increase in revenue year over year with $2.5 billion.
3. Cranial and spinal technology sales were $1.2 billion, a 6.7% increase year over year. Specialty therapies grew 4.6% with $737 million in sales.
4. Neuromodulation sales saw significant gains with $480 million, a 12.6% increase year over year.
5. Medtronic saw $1.3 billion in net income. The company is also raising its full-year guidance for fiscal year 2025 to 4.75% to 5% growth year over year.